{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-072814","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.917123+00:00","generated_at":"2026-05-17T17:18:55.821200+00:00","sec_items":["1.01","2.02","3.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CorMedix to acquire Melinta for $300M; Q2 revenue $39.7M, net income $19.8M","bullets":["Enters agreement to acquire Melinta for $260M cash + $40M stock, plus contingent milestone payments up to $25M and tiered royalties on REZZAYO and MINOCIN.","Acquisition funded by existing cash and $150M convertible notes at 4.00% due 2030; expects closing in September 2025.","Q2 2025 net revenue $39.7M (vs $0.8M YoY); net income $19.8M ($0.29 EPS) vs net loss $14.2M in Q2 2024.","Adjusted EBITDA Q2 2025 $22.4M; operating expenses $18.3M up 18% YoY driven by G&A and R&D.","Contingent payments up to $25M if FDA approves REZZAYO for prophylaxis in stem cell transplant by June 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-072814","json":"https://secwatch.observer/filing/0001213900-25-072814.json","markdown":"https://secwatch.observer/filing/0001213900-25-072814.md","text":"https://secwatch.observer/filing/0001213900-25-072814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/0001213900-25-072814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/ea0252043-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:18:55.821200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}